Zhi-Hong Chen
Overview
Explore the profile of Zhi-Hong Chen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
138
Citations
1839
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zheng M, Zhou Q, Chen H, Jiang B, Tang L, Jie G, et al.
Nat Med
. 2025 Feb;
PMID: 40016451
Genomic profiling of central nervous system (CNS) metastases has the potential to guide treatments. In the present study, we included 584 patients with non-small-cell lung cancer and CNS metastases and...
2.
Wang F, Wei X, Yang M, Lu C, Yang X, Deng J, et al.
Thorac Cancer
. 2025 Feb;
16(4):e70025.
PMID: 39994841
Background: The epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC) has a unique "cold" immune profile. DNA damage repair (DDR) genes are closely related to tumorigenesis and...
3.
Shaibu Z, Yang F, Ting L, Dzidula L, Yusuf A, Chen Z, et al.
Contemp Oncol (Pozn)
. 2024 Nov;
28(3):183-190.
PMID: 39512538
Advanced gastric and gastroesophageal junction cancer (G/GEJC) poses significant therapeutic challenges. Immune checkpoint inhibitors, particularly targeting programmed cell death ligand-1 (PD-L1), have emerged as promising agents to enhance patient outcomes....
4.
Deng J, Yang M, Yang X, Chen Z, Xu C, Zhou Q
BMC Cancer
. 2024 Sep;
24(1):1190.
PMID: 39333978
Background: Immune checkpoint inhibitors (ICIs) have become the recommended first-line treatment for advanced non-small cell lung cancer (NSCLC) without driver gene mutations. However, data on the failure patterns of first-line...
5.
Fang D, Wu L, Gan B, Guo C, Chen Z, Zhou S, et al.
BMC Gastroenterol
. 2024 Sep;
24(1):317.
PMID: 39289600
Background: The impact of prior SARS-CoV-2 infection on postoperative recovery of patients who underwent liver resection for hepatocellular carcinoma (HCC) remains uncertain given the lack of sufficient evidence. Aim: To...
6.
Lin J, Yin K, Yan L, Zheng M, Li Y, Zhang S, et al.
JTO Clin Res Rep
. 2024 Sep;
5(9):100704.
PMID: 39282661
Introduction: Transformation to SCLC is a resistance mechanism to tyrosine kinase inhibitor in -mutated lung adenocarcinoma (LUAD). Nevertheless, the clinical and molecular features of SCLC transformation in LUAD with leptomeningeal...
7.
Zhou S, Zhou Q, Wu L, Chen Z, Wu F, Chen Z, et al.
World J Gastrointest Oncol
. 2024 Aug;
16(8):3672-3686.
PMID: 39171172
Background: With the rapid progress of systematic therapy for hepatocellular carcinoma (HCC), therapeutic strategies combining hepatic arterial infusion chemotherapy (HAIC) with systematic therapy arised increasing concentrations. However, there have been...
8.
Li Y, Lai W, Yin K, Zheng M, Tu H, Guo W, et al.
Cell Rep
. 2024 Aug;
43(8):114613.
PMID: 39116206
Leptomeningeal metastases (LMs) remain a devastating complication of non-small cell lung cancer (NSCLC), particularly following osimertinib resistance. We conducted single-cell RNA sequencing on cerebrospinal fluid (CSF) from EGFR-mutant NSCLC with...
9.
Shi G, Liang M, Miao Q, Li X, Qiu W, Zeng T, et al.
Transl Pediatr
. 2024 Jun;
13(5):705-715.
PMID: 38840676
Background: The calcium-binding protein 4 () gene is a newly identified epilepsy-related gene that might be associated with a rare type of genetic focal epilepsy; that is, autosomal dominant nocturnal...
10.
Chen Z, Gu L, Wang B, Xiao L, Ye M, Zhou Q
J Am Chem Soc
. 2024 May;
146(22):14915-14921.
PMID: 38781401
Unactivated aliphatic alkenes are particularly desirable as starting materials because they are readily accessible in large quantities, but the enantioselective intermolecular reductive coupling of unactivated alkenes with imines is challenging....